Transcatheter mitral valve repair with the PASCAL precision system: First case in Singapore

Severe mitral regurgitation (MR) is associated with significant mortality and morbidity when left untreated.1 In patients who are not suitable for surgery, transcatheter edge-to-edge repair (TEER) provides a minimally-invasive therapeutic option. The MitraClip (Abbott Cardiovascular) is the most widely used TEER device globally, with the first human implantation performed in 2003 and the first case in Singapore and Asia in 2011.2,3 The underlying concept of the TEER technique involves grasping the anterior and posterior mitral valve leaflets and approximating them to reduce MR. Since then, other TEER devices with their own unique features have emerged, with PASCAL (Edwards Lifesciences) being the next to receive commercial approval in Europe and the US. The authors herein report the first case of TEER using the PASCAL system in Singapore and Southeast Asia at the National Heart Centre Singapore (NHCS).